» Articles » PMID: 10644271

Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy

Overview
Journal Ann Intern Med
Specialty General Medicine
Date 2000 Jan 22
PMID 10644271
Citations 359
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Although hepatic steatosis is seen with increasing frequency in clinical practice, its prevalence and risk factors are unknown.

Objective: To investigate the prevalence of and risk factors for hepatic steatosis, such as alcohol consumption and obesity.

Design: Cross-sectional, observational study.

Setting: Participants in the Dionysos Study.

Patients: 257 participants assigned to one of four categories (67 controls, 66 obese persons, 69 heavy drinkers, and 55 obese heavy drinkers).

Measurements: Ethanol intake, assessed by a validated questionnaire and expressed as daily (g/d) and lifetime (kg) consumption, and body mass, expressed as body mass index. Biochemical tests of liver and metabolic function and hepatic ultrasonography were done.

Results: The prevalence of steatosis was increased in heavy drinkers (46.4% [95% CI, 34% to 59%]) and obese persons (75.8% [CI, 63% to 85%]) compared with controls (16.4% [CI, 8% to 25%]). Steatosis was found in 94.5% (CI, 85% to 99%) of obese heavy drinkers. Compared with controls, the risk for steatosis was higher by 2.8-fold (CI, 1.4-fold to 7.1-fold) in heavy drinkers, 4.6-fold (CI, 2.5-fold to 11.0-fold) in obese persons, and 5.8-fold (CI, 3.2-fold to 12.3-fold) in persons who were obese and drank heavily. In heavy drinkers, obesity increased the risk for steatosis by twofold (CI, 1.5-fold to 3.0-fold) (P < 0.001), but heavy drinking was associated with only a 1.3-fold (CI, 1.02-fold to 1.6-fold) increase in risk in obese persons (P = 0.0053). Elevated alanine aminotransferase and triglyceride levels are the most reliable markers of steatosis.

Conclusions: Steatosis is frequently encountered in healthy persons and is almost always present in obese persons who drink more than 60 g of alcohol per day. Steatosis is more strongly associated with obesity than with heavy drinking, suggesting a greater role of overweight than alcohol consumption in accumulation of fat in the liver.

Citing Articles

Baseline Pathological Liver Function Tests in Patients With Psoriasis Support the Indication for Systemic Therapy Rather Than Being a Reason Against It: A Real-World Analysis.

Krefting F, Scheib C, Benson S, Holsken S, Placke J, Wedemeyer H Psoriasis (Auckl). 2025; 15:29-44.

PMID: 40046951 PMC: 11881625. DOI: 10.2147/PTT.S502296.


Altered gut microbial profile accompanied by abnormal short chain fatty acid metabolism exacerbates nonalcoholic fatty liver disease progression.

Yang C, Wu J, Yang L, Hu Q, Li L, Yang Y Sci Rep. 2024; 14(1):22385.

PMID: 39333290 PMC: 11436816. DOI: 10.1038/s41598-024-72909-8.


Efficacy of Addiction Pharmacotherapy in Alcohol Use Disorder and Their Effects on Liver Health.

Zhou J, Li J, Pan Q, Ayada I J Clin Transl Hepatol. 2024; 12(8):750-754.

PMID: 39130618 PMC: 11310752. DOI: 10.14218/JCTH.2024.00059.


Prevalence, characteristics, and risk factors of non-alcoholic fatty liver disease in North East of Iran: a population-based study.

AkbariRad M, Pezeshki Rad M, Nobakht H, Moodi Ghalibaf A, Firoozi A, Torshizian A BMC Gastroenterol. 2024; 24(1):212.

PMID: 38926664 PMC: 11210030. DOI: 10.1186/s12876-024-03302-y.


The Evolution in Non-Alcoholic Fatty Liver Disease Patients' Profile and the Associated Sustainable Challenges: A Multidisciplinary Perspective.

Aerts M, Rosseel Z, De Waele E Nutrients. 2024; 16(11).

PMID: 38892517 PMC: 11174485. DOI: 10.3390/nu16111584.